The American Journal of Managed Care

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Luspatercept shows higher efficacy than ESAs in increasing hemoglobin levels and sustaining improvement in LR-MDS patients. Patients treated with luspatercept achieve faster and more sustained red ...
The American Journal of Managed Care

Infection Linked With Nearly a Quarter of Deaths in Lower-Risk MDS

Infection is the leading cause of death in LR-MDS patients, responsible for 24.6% of deaths within a year of diagnosis. Key risk factors for infection include intermediate or higher IPSS-R risk, ...
ascopubs.org

Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country

Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...
Healthline

How to Manage MDS (Myelodysplastic Syndromes) Related Fatigue

Fatigue is one of the most common symptoms in myelodysplastic syndromes (MDS), and severe fatigue has been linked with less favorable mortality outcomes. Low blood cell counts (cytopenias) can drive ...
Healthline

What’s the Link Between Myelodysplastic Syndromes and Autoimmune Disorders?

Myelodysplastic syndromes (MDS) and autoimmune conditions can overlap, and each may raise the risk of the other. Up to 30% of people with MDS also have an autoimmune disorder. Autoimmune conditions ...